ABVC BioPharma, Inc. (NASDAQ:ABVC – Get Free Report) was the target of a significant decrease in short interest during the month of September. As of September 15th, there was short interest totalling 111,200 shares, a decrease of 19.1% from the August 31st total of 137,500 shares. Based on an average daily volume of 74,200 shares, the days-to-cover ratio is currently 1.5 days. Approximately 1.1% of the company’s shares are short sold.
Institutional Investors Weigh In On ABVC BioPharma
A hedge fund recently bought a new stake in ABVC BioPharma stock. Chase Investment Counsel Corp purchased a new position in ABVC BioPharma, Inc. (NASDAQ:ABVC – Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 178,377 shares of the company’s stock, valued at approximately $233,000. Chase Investment Counsel Corp owned approximately 1.69% of ABVC BioPharma at the end of the most recent reporting period. Institutional investors and hedge funds own 11.38% of the company’s stock.
ABVC BioPharma Trading Up 4.1 %
NASDAQ ABVC opened at $0.69 on Friday. The stock has a 50-day simple moving average of $0.70 and a 200 day simple moving average of $0.90. The company has a market capitalization of $7.46 million, a PE ratio of -0.30 and a beta of 0.81. ABVC BioPharma has a 12 month low of $0.60 and a 12 month high of $3.35.
About ABVC BioPharma
ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.
Featured Articles
- Five stocks we like better than ABVC BioPharma
- What Are Growth Stocks and Investing in Them
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- Using the MarketBeat Dividend Tax Calculator
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- How to Use the MarketBeat Dividend Calculator
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Receive News & Ratings for ABVC BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABVC BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.